Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
Open Access
- 8 November 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (21), 11711
- https://doi.org/10.3390/ijerph182111711
Abstract
Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs that may block biological pathways of SARS-CoV-2. Till today, several molecules have emerged as promising pharmacological agents, and more than a few medication protocols are applied during hospitalization. On the other hand, given the criticality of the disease, it is important for healthcare providers, especially those in COVID-19 clinics (i.e., nursing personnel and treating physicians), to recognize potential drug interactions that may lead to adverse drug reactions that may negatively impact the therapeutic outcome. In this review, focusing on patients with respiratory diseases (i.e., asthma or chronic obstructive pulmonary disease) that are treated also for COVID-19, we discuss possible drug interactions, their underlying pharmacological mechanisms, and possible clinical signs that healthcare providers in COVID-19 clinics may need to acknowledge as adverse drug reactions due to drug-drug interactions.This publication has 127 references indexed in Scilit:
- Role of Drug Efflux and Uptake Transporters in Atazanavir Intestinal Permeability and Drug-Drug InteractionsPharmaceutical Research, 2012
- Severe Colchicine Intoxication in a Renal Transplant Recipient on CyclosporineTransplantation Proceedings, 2012
- Recommendations for Generating, Evaluating, and Implementing Drug‐Drug Interaction EvidencePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Colchicine poisoning: the dark side of an ancient drugClinical Toxicology, 2010
- Interaction of Macrolide Antibiotics with Intestinally Expressed Human and Rat Organic Anion-Transporting PolypeptidesDrug Metabolism and Disposition, 2009
- Collaboration between pharmacists, physicians and nurse practitioners: A qualitative investigation of working relationships in the inpatient medical settingJournal of Interprofessional Care, 2009
- DrugBank: a comprehensive resource for in silico drug discovery and explorationNucleic Acids Research, 2006
- Acute Myopathy in a Patient with Concomitant Use of Pravastatin and ColchicineAnnals of Pharmacotherapy, 2005
- Interactions between Corticosteroids and 2-Agonists in Asthma and Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2004
- Non-antiarrhythmic drugs prolonging the QT interval:considerable use in seven countriesBritish Journal of Clinical Pharmacology, 2002